Get started
Author

Carol A. Morris-Tilden

Observed names: C.A. Morris-Tilden, Carol Morris-Tilden
Observed institution: Seagen (United States)
OpenAlex ID: A5073992829
Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate
2008 · Svetlana O. Doronina, Tim D. Bovee, et al. · Bioconjugate Chemistry · 182
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas
2009 · Hans-Peter Gerber, May Kung-Sutherland, et al. · Blood · 85
PDF
Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
2008 · Julie A. McEarchern, Leia M. Smith, et al. · Clinical Cancer Research · 83
Anti-leukemic activity of Lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia
2009 · May Kung Sutherland, Changpu Yu, et al. · mAbs · 43
PDF
A Humanized Anti-CD70 Monoclonal Antibody Targets CD70-Expressing Multiple Myeloma.
2005 · Julie A. McEarchern, Charlotte McDonagh, et al. · Blood · 4
Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies
2007 · Hans‐Peter Gerber, Carol A. Morris-Tilden, et al. · Molecular Cancer Therapeutics · 3
SGN-70, a Humanized Anti-CD70 Antibody, Targets CD70-Expressing Hematologic Tumors.
2006 · Julie A. McEarchern, Charlotte F. McDonagh, et al. · Blood · 1
Supplementary Figures S1-S4 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
2023 · Julie A. McEarchern, Leia M. Smith, et al.
Supplemental data Figure 4 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
2023 · Julie A. McEarchern, Leia M. Smith, et al.
Supplemental data Figure 1 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
2023 · Julie A. McEarchern, Leia M. Smith, et al.
Supplemental data Figure 2 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
2023 · Julie A. McEarchern, Leia M. Smith, et al.
Data from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
2023 · Julie A. McEarchern, Leia M. Smith, et al.
Data from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
2023 · Julie A. McEarchern, Leia M. Smith, et al.
Supplementary Table 1 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
2023 · Julie A. McEarchern, Leia M. Smith, et al.
Supplemental data Figure 3 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
2023 · Julie A. McEarchern, Leia M. Smith, et al.
Supplemental data Figure 4 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
2023 · Julie A. McEarchern, Leia M. Smith, et al.
Supplemental data Figure 3 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
2023 · Julie A. McEarchern, Leia M. Smith, et al.
Supplemental data Figure 1 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
2023 · Julie A. McEarchern, Leia M. Smith, et al.
Supplemental data Figure 2 from Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
2023 · Julie A. McEarchern, Leia M. Smith, et al.
527 POSTER Improving the therapeutic window of antibody-drug conjugates through novel linker design
2008 · D.L. Meyer, S.O. Doronina, et al. · European Journal of Cancer Supplements
SGN-33, Lintuzumab, Demonstrates Anti-Leukemic Activity in Preclinical Models of AML.
2007 · May S.K. Sutherland, Changpu Yu, et al. · Blood
Works count: 21
Citation count: 401
H-index: 4
I10-index: 4
Year
Topic
Type